Actym Therapeutics Appoints Thomas Smart as CEO
BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
- BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics , pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer.
- The STACT approach provides both efficacy and safety advantages by leveraging a genetically modified bacteria vehicle, systemically administered, that achieves tissue-specific delivery of large nucleic acid payloads," said Thomas Smart, CEO of Actym.
- Mr. Smart has a distinguished 25-year career as a biotech executive, demonstrating dynamic leadership in roles such as CEO, CBO, SVP, and Board Member.
- Before joining Actym Therapeutics, Mr. Smart founded Gravitas Therapeutics, where he served as CEO and Board Chair and orchestrated the acquisition and subsequent sale of the clinical-stage antifungal asset, GR-2397, to Basilea Pharmaceutica Ltd (SIX: BSLN) in October 2023.